Table 1.
Patient characteristics and lipids at baseline (intention-to-treat analysis)
| Characteristics | Patients (n = 612) |
|---|---|
| Age, mean (SD), years | 61.6 (11.1) |
| Male, n (%) | 394 (64.4) |
| FH, n (%) | 311 (50.8) |
| Hypertension, n (%) | 423 (69.1) |
| CHF, n (%) | 82 (13.4) |
| DM, n (%) | 169 (27.6) |
| Type 1 | 10/169 (5.9) |
| Type 2 | 154/169 (91.1) |
| Insulin dependency | 56/169 (33.1) |
| Any cardiovascular disease, n (%) | 552 (90.2) |
| CHD | 443 (72.4) |
| ACS | 202 (33.0) |
| PAD | 81 (13.2) |
| Cerebrovascular disease | 56 (9.2) |
| Total statin intolerance,an (%) | 277 (45.3) |
| Partial statin intolerance,bn (%) | 169 (27.6) |
| Apheresis, n (%) | 50 (8.2) |
| Lipids, mean (SD), mmol/L [mg/dL] | |
| LDL-C | 4.7 (1.6) [180.5 (60.7)] |
| Non-HDL-C | 5.5 (1.9) [213.9 (72.2)] |
| HDL-C | 1.3 (0.5) [50.8 (19.7)] |
| Total cholesterol | 6.9 (2.0) [266.6 (76.1)] |
| TGs | 2.9 (4.3) [256.8 (377.9)] |
| Median (Q1:Q3) | 2.0 (1.5:3.1) [178.0 (129.0:268.0)] |
ACS acute coronary syndrome, CHF congestive heart failure, CHD coronary heart disease, DM diabetes mellitus, FH familial hypercholesterolemia, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, PAD peripheral arterial disease, SD standard deviation, TG triglyceride
aStatin intolerance was defined as an inability to tolerate two or more statins (one statin at the lowest daily starting dose [i.e., rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg, or pitavastatin 2 mg], and another statin at any dose) owing to unexplained skeletal muscle-related symptoms, other than as a result of strain or trauma, that began or increased during statin treatment and resolved with statin discontinuation
bPartial statin intolerance was defined as an inability to tolerate sufficient statin dose to reach treatment target